Switching From Ozempic to Wegovy: What You Need to Know

Step 1: Understand why the two licences are different

Ozempic and Wegovy share an active ingredient, semaglutide, yet they are not the same product in the eyes of UK regulators. Ozempic is licensed for type 2 diabetes. Wegovy is the formulation the MHRA has authorised for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure or obstructive sleep apnoea. The distinction matters for weight loss specifically: a prescriber issuing Ozempic for weight management rather than diabetes would be working outside the product's licensed indication, which is why many people want to move to the correctly licensed option.

Wegovy also reaches a higher maintenance dose. The standard Wegovy pathway runs from 0.25 mg up to 2.4 mg weekly, and the MHRA approved a dedicated 7.2 mg single-dose pen in April 2026 for adults with obesity. Ozempic tops out at 2 mg for diabetes management. So if you want the full licensed dose range for weight management, Wegovy is the right product.

Step 2: Know what a clinical switch actually involves

Moving from one semaglutide product to another is not simply a matter of picking up a different pen. A prescriber will want to know your current dose, how long you have been on it, how you have tolerated it and whether your weight-management goals are clearly documented. The practical process of switching typically means aligning your Wegovy starting dose with your most recent Ozempic dose, rather than beginning the titration from scratch at 0.25 mg, though that clinical call belongs to the prescriber reviewing your case.

There is no wash-out period between the two products; because both contain semaglutide, you would not stop one and wait before starting the other. The transition is more like a product transfer than a fresh start. That said, a proper consultation is still required, because the prescriber needs to confirm eligibility under the Wegovy licence, check your current health picture, and document the rationale for the switch. Evidence of your current treatment will be requested.

Step 3: Compare the two products side by side

The table below sets out the key factual differences to support your conversation with a prescriber. Numbers are drawn from the published clinical programme and NHS semaglutide guidance.

Neither product is "better" in an absolute sense. The right choice depends on your clinical picture. Wegovy's full licensed profile is worth reviewing before your consultation.

What IS licensed for weight loss, and how to get it

If you are looking to switch from Ozempic because you want an appropriately licensed weight-management medicine, the UK-licensed options are Wegovy (semaglutide injection or, since June 2026, the Wegovy tablet) and Mounjaro (tirzepatide), the only dual GIP and GLP-1 receptor agonist approved in the UK. Mounjaro operates on two receptor pathways rather than one, and the SURMOUNT-5 trial published in 2025 showed greater average weight reduction with tirzepatide compared with semaglutide 2.4 mg over 72 weeks, though both are effective for the right patient.

Ozempic is not dispensed by nume for weight loss, and a consultation on that product is not something we offer. If the question is which semaglutide product fits your situation, our prescribers can work through that with you during a free consultation. The storage routine changes too: Wegovy pens live in the fridge door just as Ozempic does, so that part of your weekly habit carries over without adjustment.

For anyone already on Wegovy wondering about the reverse direction, switching back to a diabetes-licensed semaglutide product raises similar licensing questions and equally needs prescriber input. Which medicine suits you is a clinical decision our prescribers make with you. Speak to our prescribers to start that conversation.